Funding Opportunities

When we become aware of any upcoming funding opportunities that we think might be of interest they will included here.



Myotonic Dystrophy Foundation – Funding call for the Development of a Genome Editing Strategy for Myotonic Dystrophy Type 1

Closing date – 30 November 2018

The Myotonic Dystrophy Foundation (MDF) is pleased to announce a Request for Applications (RFA) for the Development of a Genome Editing Strategy for Myotonic Dystrophy Type 1 (DM1). Through this RFA, MDF recognizes a need to advance genome editing technology and evaluate its potential as a therapy for use in DM1.

MDF intends to issue two 2-year awards of up to $250,000 total cost for projects that address the evaluation of genome editing strategies that target the DMPK gene. The focus of the RFA is on early stage discovery and development of in vivo genome editing technologies in academic laboratories or other nonprofit research institutions, utilizing state-of-the-art knowledge.

Collaborations between experts in genome editing technologies and those with strong track records in myotonic dystrophy research are strongly encouraged.

Find out more – www.myotonic.org


The ERNs are co-funded by the
European Union (Health Programme and CEF)

EU Commission


“EURO-NMD is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Union (Health Programme and CEF).
For more information about the ERNs and the EU health strategy,
please visit ec.europa.eu/health/ern